Research Updates

Back to feed
PubMed
Research review

High importance

Oct 22, 2026

Molecular-genetic mechanisms of cerebral arteriovenous malformations: A systematic review of germline, somatic and experimental evidence.

View original source

Why it matters

Understanding the genetic and molecular mechanisms of AVM formation can lead to improved diagnostics and the development of targeted therapies, enhancing treatment options and outcomes for patients with hereditary hemorrhagic telangiectasia and related conditions.

Objective

To consolidate current knowledge on the molecular and genetic mechanisms behind cerebral arteriovenous malformations (AVMs), particularly inherited syndromes and sporadic lesions, and to identify potential therapeutic targets.

Results

The review included 44 primary studies and 20 reviews/meta-analyses. Inherited AVM syndromes were primarily linked to germline variants in the TGF-β/BMP pathway and other regulatory genes. Sporadic AVMs frequently had somatic mutations in the RAS/MAPK pathway. Findings indicated that both germline and somatic mutations impact the formation and behavior of AVMs, with a complex interplay involving local modifying events and genetic susceptibility variants affecting hemorrhagic risks.

Methods

Conducted a systematic review by searching databases (MEDLINE, Embase, Web of Science Core Collection, Scopus) for studies on genetic, molecular, or epigenetic data concerning cerebral AVMs. Two independent reviewers screened records and assessed full texts, with qualitative synthesis due to heterogeneity in study designs and outcomes.

Limitations

The review highlighted substantial heterogeneity among studies, which limited the ability to quantitatively synthesize results. The need for high-sensitivity assays to detect low-level mutations and the requirement for standardized methodology in the future were also noted.

For your doctor:

PMID: 42911426

DOI: 10.1007/s10143-026-04541-1

Abstract

Cerebral arteriovenous malformations (AVMs) are high-flow vascular anomalies that carry a considerable burden of haemorrhagic morbidity. Work over the past decade has shown that both inherited syndromes and apparently sporadic lesions can be traced to alterations in a handful of signalling pathways, but the relevant evidence sits awkwardly between human genetic studies, animal models, and molecular profiling experiments. To bring together the current evidence on the molecular and genetic underpinnings of cerebral AVM formation, clinical course, and candidate therapeutic targets. We searched MEDLINE (PubMed), Embase, Web of Science Core Collection, and Scopus from inception to 1 January 2026. Records were screened, and full texts assessed, by two reviewers working independently. Studies were eligible if they reported genetic, molecular, or epigenetic data on cerebral AVMs. Because of substantial heterogeneity in designs and outcomes, evidence was synthesised qualitatively. Of 343 records, 44 primary studies (28 clinico-genetic and 16 experimental) together with 20 reviews and meta-analyses met inclusion. Inherited AVM syndromes largely reflected germline variants in the TGF-β/BMP network (ENG, ACVRL1, SMAD4, GDF2/BMP9) or in arteriovenous-specification regulators (RASA1, EPHB4); penetrance was incomplete and there was support for local modifying "second-hit" events. Resected sporadic cerebral AVMs often carried somatic activating mutations in the RAS/MAPK cascade-mostly KRAS, less often BRAF-at low variant allele fractions that demanded high-sensitivity assays. Endothelial-specific activation of KRAS or BRAF reproduced AVM-like phenotypes in vivo and showed MEK-ERK dependence. Susceptibility variants (notably at 9p21/ANRIL), inflammatory mediators, extracellular-matrix remodelling, and epigenetic changes appear to fine-tune lesion behaviour and haemorrhagic risk. Syndromic predisposition and clonal somatic events in endothelium converge on a small set of developmental signalling axes that govern angiogenesis and vessel-wall maturation. Diagnostics anchored in this biology, together with pathway-targeted therapy, now need prospective evaluation, paired with standardised approaches for detecting low-level mosaicism.